The Valley Desk

NCT07581002 · Interventional trial

A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML)

Overall registry status Recruiting

Phase 2 · Phase 3

Conditions Acute Myeloid Leukemia

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov